Sostravel.com receives a research report by Arrowhead detailing a 2.76x potential upside in price
17.11.2022 10:00:00 EET | Business Wire | Press release
Sostravel.com S.p.A. (Euronext Growth Milan, ticker: SOS), digital operator offering booking services, digital itineraries including information on flights and airports, car rental, experiences, and proprietary services including the Lost Luggage Concierge through the Sostravel and Flio apps, as well as through the platforms www.Sostravel.com and www.amareitalia.com, announces that today, Arrowhead, an Independent Research company based in New York, providing due diligence and valuation reports on selected listed companies, published a research report on Sostravel, with a Fair Share Valuation Bracket of 2.01 to 2.50 EUR, when the share price of the company (ticker BIT: SOS) trades at ~0.90 EUR, for a 2,760% potential appreciation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115006003/en/
Sostravel App offers booking services, digital itineraries including flight and airport information, car renting, experiences, and insurance services. The company operates the Lost Luggage Concierge proprietary service and is expanding into telehealth services designed for travellers. (Graphic: Business Wire)
Sostravel.com S.p.A. (SOS), headquartered in Italy, operates in the global travel and tourism (T&T) industry. It has a presence online, on Google Play, and Apple App Store, and in 23 airports in Europe, America, and Asia. The company was founded in 2017 as a spin-off from TraWell Co. (previously Safe Bag).
On November 1st, the company finalized the merger with DDC, a company with strong expertise in digital marketing for traveling and an established booking platform. The app, now merged with DDC allows customers to engage in bookings of airplanes, hotels, and cars, build a digital itinerary with other services, such as tours and events, and access value-added services like Lost Luggage Concierge and telehealth. The strategy is to attract potential customers with booking services and offer high-margin services through the app, focusing on the leisure and holiday segments.
The new post-merger entity is positioned to capture the growth in digital travel revenues, already owning a significant share of the passenger information sector, Sostravel aims to consolidate the world of traveler information and services, with the only integrated app on the market.
Based on its due diligence and valuation estimates, Arrowhead believes that SOS’s fair share value lies in the EUR 2 to EUR 2.50 bracket, which has been calculated using a blended valuation method: with 60% weighting to a discounted cash flow (DCF) method and 40% weighting to a Comparable Companies Valuation method.
Sostravel is listed on Euronext Growth Milan, ticker BIT: SOS
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115006003/en/
Contact information
For further information:
Sostravel.com S.p.A.
Investor Relations
Edoardo Zarghetta
investor.relations@Sostravel.com
www.Sostravel.com
Ph: +39 0331 1587117
Fax: +39 0331 1582452
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 15:05:00 EEST | Press release
Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinreich, Global Head of R&D, Merck. “With enpatoran, we aim to target the underlying drivers of lupus and redefine how to approach the disease by understanding both visible skin manifestations and systemic activity.” Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor designed to modulate pathways central to lupus-related inflammatio
The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 15:00:00 EEST | Press release
The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i
Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 15:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are: Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of Michael Kors’ strongest performance periods. Titan of Europe: Ash Cummings, Ecommerce Fraud Prevention Manager, Gymshark A
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release
CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom